Sign in

    Abdul Kader Puranwala

    Research Analyst at ICICI Securities

    Abdulkader Puranwala is a Research Analyst at ICICI Securities, specializing in pharmaceuticals and healthcare sector coverage with a focus on leading companies such as Cipla, Alkem Laboratories, and HealthCare Global Enterprises. Since joining ICICI Securities in 2023 after previous experience at Anand Rathi, he has been recognized for providing in-depth financial analysis, demonstrating expertise through detailed research reports evaluating key metrics like EBITDA margins, RoE, and EPS growth for covered firms. Puranwala holds a SEBI Research Analyst Registration (INH000000990), underscoring his professional credentials and regulatory compliance. Throughout his career, he has built a reputation for rigorous research and sector insight within the Indian equity market.

    Abdul Kader Puranwala's questions to DR REDDYS LABORATORIES (RDY) leadership

    Abdul Kader Puranwala's questions to DR REDDYS LABORATORIES (RDY) leadership • Q1 2026

    Question

    Abdul Kader Puranwala of ICICI Securities inquired about the potential pricing strategy for semaglutide and whether the planned 500-600 bps of cost savings would come from investments in the NRT and nutraceuticals businesses.

    Answer

    CEO Erez Israeli stated that semaglutide pricing will be set as high as the market allows, depending heavily on competition and reimbursement. He clarified that the potential cost savings are from discretionary areas like travel and consultants, not from cutting investments that support growth drivers like the recently acquired NRT business. The priority remains growing the company.

    Ask Fintool Equity Research AI